4 March 2021

ASX ANNOUNCEMENT

ImpediMed Achieves Milestone 200,000 SOZO Patient Tests

Brisbane, Australia – ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health is pleased to announce that SOZO customers have collectively taken over 200,000 patient tests since commercial launch in October 2017. In the prior quarter (Q2 FY'21), more than 28,000 patient tests were conducted in the one quarter alone.

It took the company 32 months to achieve the milestone of the first 100,000 patient tests. The next 100,000 patient tests took just 13 months. We expect testing rates to continue to accelerate as we gain reimbursement for Lymphoedema and commercialise the Heart Failure and Renal Failure indications.

"This is a significant milestone for our company, but more importantly for the patients whose lives have been dramatically impacted by the reduction in lymphoedema rates from SOZO testing. For the company, we are building a large dataset which will be very valuable in providing new insights into the course and care of a large number of chronic disease states," said Richard Carreon, Managing Director and CEO of ImpediMed.

"As reported earlier, patient testing dropped significantly in cancer centers as COVID-19 cases in the US spiked. This falloff in testing occurred in the closing weeks of December and carried over through January. For the past several weeks, as COVID-19 cases subsided, patient testing noticeably improved, indicating March should be a strong month for testing. Although the quarter (Q3 FY'21) is likely only to show modest growth versus the previous quarter (Q2 FY'21), the data demonstrates significant year on year growth and, importantly, points to a strong recovery in patient testing heading into the fourth quarter," he continued.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:
Mike Bassett, ImpediMed
T: +61 407 431 432
E: mbassett@impedimed.com

Media Contact:
Kyahn Williamson, WE Communications
T: +61 3 8866 1200
E: kwilliamson@we-worldwide.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform
SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO captures a vast array of data over a wide spectrum of frequencies from 3 kHz to 1000 kHz, which can be used in multiple applications. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: https://www.impedimed.com/products/sozo/

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.